Announcements Trials

Browse Landscape

Phase

Phase 1 4 Phase 1/2 3 Phase EARLY_PHASE1 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 174 Myeloid 64 Lymphoid 28 Thoracic 7 Gastrointestinal 5 Classical hematology 5 Breast 4 Plasma cell 3 Genitourinary 3 Sarcoma 2 Head & Neck 2 Gynecologic 2 Dermatologic 1 CNS 1

Conditions

Interventions

Temozolomide 258 Radiotherapy 147 Bevacizumab 141 Etoposide 68 Cyclophosphamide 68 Carboplatin 66 Magnetic Resonance Spectroscopy 58 Irinotecan 53 Cisplatin 52 Vincristine 45 Filgrastim 43 pembrolizumab 40 Radiosurgery 36 Nivolumab 36 Radiation 34 Topotecan 31 Doxorubicin 30 Specimen Handling 29 sargramostim 28 Lomustine 27 Erlotinib Hydrochloride 27 Peripheral Blood Stem Cell Transplantation 25 Carmustine 25 Thiotepa 24 Everolimus 23 Chemotherapy, Adjuvant 23 Surgical Procedures, Operative 22 Isotretinoin 22 Ipilimumab 22 Melphalan 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Azacitidine × CNS × Clear all

NCT03666559 2024-02-29

AGIR

Assistance Publique - Hôpitaux de Paris

Phase 2 Unknown

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡